ArticleIndian dermatology online journal2025
The Enigma of Paradoxical Reactions to Biological Therapies.
Article in Indian dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractThe advent of targeted biological agents has revolutionized the treatment approach for immune-mediated inflammatory diseases (IMIDs) in rheumatology and dermatology. However, these agents can lead to paradoxical immune-mediated inflammatory reactions (PRs), presenting challenges in clinical management. This case series aims to demonstrate diverse PRs associated with biologic therapies in IMID patients, shedding light on their clinical manifestations and management strategies. Five cases of IMID patients receiving targeted biologic therapies who developed PRs were retrospectively analyzed. Clinical presentations, histopathological findings, and treatment outcomes were documented. The PRs observed included pityriasis rosea-like drug reactions, eczematous reactions, lichenoid drug eruptions, and fixed drug eruptions. Histopathological examination revealed characteristic patterns corresponding to each PR type. Management strategies involved discontinuation or switching of biologic agents, resulting in resolution of cutaneous manifestations. This case series underscores the importance of recognizing and managing PRs in IMID patients undergoing biologic therapy. Further research is warranted to elucidate underlying mechanisms and guide therapeutic decisions, particularly with the emergence of biosimilars and potential cross-reactivity concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.